PVI
LCTX icon

Pine Valley Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Pine Valley Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,000
Closed -$16.3K – 538
2024
Q3 		$16.3K Hold
18,000
– – ﹤0.01% 511
2024
Q2 		$18K Hold
18,000
– – ﹤0.01% 479
2024
Q1 		$26.6K Buy
+18,000
New +$20.4K ﹤0.01% 483

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Pine Valley Investments's LCTX Position: Q4 2024 in Review

Pine Valley Investments sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 18,000 shares — an estimated $16.3K sold.

Pine Valley Investments first reported a position in LCTX in Q1 2024 and held it in 3 quarters. The position peaked at $26.6K in Q1 2024. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Pine Valley Investments reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Pine Valley Investments sold 18,000 Lineage Cell Therapeutics shares in Q4 2024, an estimated $16.3K.
  • Pine Valley Investments first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 3 quarters.
  • Pine Valley Investments's Lineage Cell Therapeutics position peaked at $26.6K in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Pine Valley Investments's 13F filing for Q4 2024, filed 4 Feb 2025.